Parkinson’s Niche To Expand With New Drugs, More Patients
Executive Summary
Newron’s new Parkinson’s disease therapy, Xadago, approved in the US after a regulatory delay, is expected to be the first of several new products to be introduced in this long-neglected therapeutic sector.
You may also be interested in...
Acorda's Parkinson's Drug Tozadenant May Not Survive Safety Setback
The safety problems reported for tozadenant – including deaths – have not been reported for other A2a receptor inhibitors and the company sees them as "idiosyncratic," stirring doubts about a commercial future.
Newron's Parkinson's Disease Drug Xadago Priced At $600-700/Month
First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.
Newron's Parkinson's Drug Xadago Has Narrower Indication Than Teva's Azilect
After overcoming regulatory hurdles, Newron may have tough time competing in US against market stalwart Azilect; eight Parkinson's drugs are in Phase III trials.